Verquvo

For the treatment of symptomatic chronic heart failure (HF) as an adjunct to standard-of-care therapy in adult patients with reduced ejection fraction who are stabilized after a recent HF decompensation event, if all the following conditions are met:

(a) Left ventricular ejection fraction (LVEF) less than 45%;

(b) New York Heart Association (NYHA) class II to IV symptoms;

(c) HF decompensation event requiring hospitalization within the previous 6 months and/or intravenous diuretic treatment for HF (without hospitalization) within the previous 3 months;

(d) Vericiquat is used in combination with standard-of-care* HF therapy; and

(e) Initiated under the supervision of a prescriber who is experienced in the management of HF.

* Standard-of-care HF therapy includes one medication from each of the following categories, unless there is a contraindication or intolerance:

(a) angiotensin receptor-neprilysin inhibitor (ARNI) or angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB);

(b) beta blocker;

(c) mineralocorticoid receptor antagonist (MRA); and

(d) sodium-glucose cotransporter-2 (SGLT2) inhibitor